GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Dividend Payout Ratio

ALPMY (Astellas Pharma) Dividend Payout Ratio : 0.00 (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Astellas Pharma's Dividend Payout Ratio for the months ended in Dec. 2024 was 0.00.

The historical rank and industry rank for Astellas Pharma's Dividend Payout Ratio or its related term are showing as below:


During the past 13 years, the highest Dividend Payout Ratio of Astellas Pharma was 12.12. The lowest was 0.33. And the median was 0.47.

ALPMY's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.36
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-03-14), the Dividend Yield % of Astellas Pharma is 4.79%.

During the past 13 years, the highest Trailing Annual Dividend Yield of Astellas Pharma was 5.02%. The lowest was 1.40%. And the median was 2.40%.

Astellas Pharma's Dividends per Share for the months ended in Dec. 2024 was $0.00.

During the past 12 months, Astellas Pharma's average Dividends Per Share Growth Rate was 10.80% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 18.60% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 13.50% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 8.90% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Astellas Pharma was 52.50% per year. The lowest was 1.30% per year. And the median was 6.75% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Astellas Pharma Dividend Payout Ratio Historical Data

The historical data trend for Astellas Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Dividend Payout Ratio Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.65 0.85 1.12 11.85

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.77 -

Competitive Comparison of Astellas Pharma's Dividend Payout Ratio

For the Drug Manufacturers - General subindustry, Astellas Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Dividend Payout Ratio falls into.



Astellas Pharma Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Astellas Pharma's Dividend Payout Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Mar. 2024 )/ EPS without NRI (A: Mar. 2024 )
=0.462/ 0.039
=11.85

Astellas Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2024 )/ EPS without NRI (Q: Dec. 2024 )
=0/ -0.355
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma (OTCPK:ALPMY) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Astellas Pharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

From GuruFocus